• Home
  • About Us
  • Contact
  • Subscribe
  • Your Account
  • Login
No Result
View All Result
Tuesday, June 6, 2023
Alternatives Watch
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe
No Result
View All Result
Alternatives Watch
No Result
View All Result

UBS kicks MPM Capital oncology impact fund into record territory

Sergio BarretobySergio Barreto
October 7, 2021
in Manager News, Private Equity
UBS boosts MPM Capital oncology impact fund into record territory

By twenty20photos/Envato Elements

ShareTweetShareSendSend

MPM Capital expected to raise $650 million for its second Oncology Impact Fund (OIF 2), which would have been more than enough to snatch the title of largest biotech impact investment fund ever from its own OIF 1, which closed in 2016.

Then UBS pumped $650 million into the fund on behalf of clients from around the world, including the U.S., the UK, Europe and Asia. MPM and its BioImpact Capital team directly raised another $200 million, bringing OIF2, putting OIF2 within striking distance of doubling its predecessor’s $471 million take. UBS was also a partner on OIF 1.

The firms have pledged to donate a portion of their success fees from OIF 2, as well as a royalty from treatments that end up being marketed by any startups it funds, to the American Association for Cancer Research (AACR) and to the UBS Optimus Foundation. AACR will use the proceeds to help fund grants for next-generation cancer research, while the UBS Optimus Foundation will use the proceeds to expand access to cancer care in the developing world. Performance fees from OIF 1 have already generated $8 million for these causes.

The generosity displayed by the firms is definitely a case of doing well by doing good, as global spending on oncology drugs is expected to reach $269 billion in 2025, up from $164 billion in 2020, according to the Global Oncology Report issued this week by the IQVIA Institute. Among the success stories backed by OIF 1 are Elevate Bio, which closed a $525 million Series C in June to advance its innovative cell and gene therapies, and Orna Therapeutics, which completed an $80 million Series A in February to develop novel cell therapeutics based on engineered circular RNA.

“OIF 2 will focus on oncology as well as cell, gene, and RNA therapies, building off the strong performance of OIF 1,” said Dr. Ansbert Gadicke, managing partner of BioImpact Capital and managing director of MPM. The fund will invest 80% of its capital into private companies, with the remaining 20% going into public companies.

“We are proud to connect our clients with brilliant scientists around the world who are working hard to alleviate the pain and suffering caused by cancer,” added Mark Haefele, chief investment officer at UBS Global Wealth Management. “With more than $1 billion raised so far, this is what reimagining the power of investing and connecting people for a better world can look like.”

Tags: Life SciencesMPM CapitalUBS
ShareTweetShareSendSend
Previous Post

Manulife closes second co-investment fund at $683m

Next Post

New York Life’s Chanda joins Monroe Capital

Related Posts

Music Beats Cancer supports early stage biotechs, plans NYC benefit concert
Features

Music Beats Cancer supports early stage biotechs, plans NYC benefit concert

People moves in the alternative investments industry
Consultants

People moves for week of June 2

Mass PRIM adds $640m to diverse PE strategies
Pensions

Mass PRIM adds $640m to diverse PE strategies

Adams Street sees strong secondaries demand with $3.2bn fund close
Private Equity

Adams Street sees strong secondaries demand with $3.2bn fund close

IMRF approves $315m in new commitments
Pensions

IMRF approves $315m in new commitments

Next Post
New York Life's Chanda joins Monroe Capital

New York Life's Chanda joins Monroe Capital

Log In/Out

Lost your password?

Search the AW Archives

No Result
View All Result

Recent News

Private equity mega-deals shine

Private equity mega-deals shine

HPS attracts $10bn for senior lending

HPS attracts $10bn for senior lending

Music Beats Cancer supports early stage biotechs, plans NYC benefit concert

Music Beats Cancer supports early stage biotechs, plans NYC benefit concert

CDPQ hires in NYC, taps brakes on China investments

CDPQ hires in NYC, taps brakes on China investments

Be an Alts Insider

Sign up for your FREE daily alts news briefing

Subscribe

Subscribe to AW
Alternatives Watch

© 2019-2022, All Rights Reserved  |  BMV Digital

Navigate Site

  • Investor News
  • Private Equity
  • Private Credit
  • Hedge Funds
  • Real Estate/Infrastructure
  • Subscribe
  • Your Membership
  • Terms of Service
  • Privacy Policy

Follow Us

No Result
View All Result
  • Home
  • Hedge Funds
    • Manager News
    • Mandates
    • Service Provider News
    • CTAs/Managed Futures
  • Private Equity
    • Manager News
    • Mandates
    • Service Provider News
  • Private Credit
    • Manager News
    • Mandates
    • Service Provider News
  • RE/Infrastructure
    • Manager News
    • Mandates
    • Service Provider News
  • Investor News
    • Endowments and Foundations
    • ESG
    • Pensions
    • Platforms
    • Consultants
  • Research
    • Investor Scorecard
    • Manager Scorecard
  • Subscribe

© 2019-2022, All Rights Reserved  |  BMV Digital

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Be an alts insider

Start your days in the know with our free newsletter

No, I don't want to be an alts insider

Thank

You!

Follow us
on LinkedIn

Lost your password?

This Website Uses Cookies
We use cookies on our website to provide necessary functions. By clicking “Accept”, you consent to the use of all strictly necessary cookies.
Do not sell my personal information.
Cookie Settings Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Save & Accept
Powered by CookieYes Logo